COVID-19 Vaccination and Alzheimer's Risk

This research investigates the potential impact of COVID-19 vaccination on the risk of developing Alzheimer's disease among individuals aged 60 and above. The focus is on identifying evidence from both observational studies and randomized controlled trials (RCTs) that explore the relationship between COVID-19 vaccination and Alzheimer's disease incidence. We aim to uncover specific outcomes related to cognitive decline or dementia onset following vaccination. Key areas of interest include the immunological mechanisms potentially linking vaccination to neuroprotection, as well as any epidemiological data highlighting changes in Alzheimer's disease prevalence post-vaccination. The investigation considers variations in vaccine types and regimens and their differential effects on Alzheimer's risk. By examining studies conducted within the last five years, this research seeks to provide insights into whether COVID-19 vaccination could serve as a modulatory factor in Alzheimer's disease risk among the elderly population.